A meeting of the committee underscored how many uncertainties lie ahead, including whether a vaccine that works better against variants can be ready by fall.
With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.